Ocean Pollution: Pharmaceuticals' Impact On Marine Life

Pharmaceuticals are increasingly being found in the world's oceans, causing concern for the health of marine life and ecosystems. The sources of this pharmaceutical pollution are varied and include human waste, hospital discharges, and drug manufacturing. In addition, the disposal of unused medication in landfills and sewage treatment plants has led to leakage directly into the ocean. While there has been significant investment in researching the impacts of pharmaceuticals in freshwater and terrestrial ecosystems, data on their effects in marine environments is lacking. This is a pressing issue, as pharmaceuticals can cause behavioural changes, hormone disruption, and toxicity in aquatic organisms. Furthermore, the development of antibiotic resistance in bacteria due to antibiotic pollution is also a growing concern. To address this global problem, alternative add-on systems for traditional wastewater treatment plants are being developed, and legislation is needed to ensure the proper elimination of pharmaceuticals from wastewaters.

Pharmaceuticals enter oceans through sewage systems, rainwater runoff, and factory discharges

Pharmaceuticals enter oceans in multiple ways, including sewage systems, rainwater runoff, and factory discharges. These entry points can have significant ecological impacts, affecting the health and behaviour of various organisms and ecosystems.

Sewage systems are a significant pathway for pharmaceuticals to enter oceans. Wastewater treatment plants are often not equipped to remove medicines entirely, allowing pharmaceuticals to pass through and enter surface water. This treated wastewater then flows downstream, potentially impacting drinking water sources for other communities. In some cases, sewage can be discharged directly into marine environments through coastal outfalls or rivers receiving wastewater effluents. Additionally, ships and boats may release treated or untreated sewage into the sea, further contributing to pharmaceutical pollution in oceans.

Rainwater runoff is another contributor to pharmaceutical pollution in oceans. When pharmaceuticals are disposed of improperly, such as by flushing leftover medications, they can enter stormwater systems and eventually make their way into oceans. Rainwater can also carry pharmaceuticals from agricultural or industrial sites, where they are used in intensive aquaculture or manufacturing processes.

Factory discharges, including those from pharmaceutical manufacturing industries, can introduce a significant amount of pharmaceutical pollution into oceans. The manufacturing process of drugs releases bioactive substances as pollution, and wastewater from these factories may contain high concentrations of pharmaceuticals. These discharges can enter waterways or the marine environment, impacting aquatic life and ecosystems.

The presence of pharmaceuticals in oceans has been shown to have detrimental effects. For example, antibiotics can inhibit the production of chloroplasts in algae, disrupting photosynthesis, and contributing to the development of antibiotic-resistant bacteria. Additionally, hormones from contraceptive pills have been found to interfere with the reproductive systems of fish, causing behavioural changes and physical abnormalities.

Addressing the issue of pharmaceutical pollution in oceans requires a multifaceted approach. Improving wastewater treatment technologies to effectively remove pharmaceuticals is essential. Additionally, proper disposal of pharmaceuticals, such as through take-back programs or safe disposal methods, can help reduce their entry into sewage systems and rainwater runoff. Finally, stricter regulations and treatment processes for factory discharges are necessary to minimize the release of pharmaceutical pollutants into marine environments.

Drug manufacturing and agriculture are major sources of pharmaceutical pollution

Pharmaceuticals are indeed found in ocean pollution. While there has been significant investment in researching the impacts of pharmaceuticals in freshwater and terrestrial ecosystems, there is a notable absence of data for pharmaceuticals in marine environments in many regions, including Africa, South America, and small island nations in Oceania. However, studies have detected various pharmaceuticals in marine sediments, and it is known that sediments can act as a secondary source of pharmaceutical pollution.

Drug manufacturing and agriculture are significant contributors to pharmaceutical pollution. Direct emissions from drug manufacturing facilities have been identified as a source of high environmental discharges of pharmaceutical pollutants. In some cases, the levels of contamination downstream from drug manufacturing plants have been 10 to 1,000 times higher than those at comparable facilities. The discovery of oestrogens in sewage effluents and their impact on fish populations sparked increased interest in pharmaceuticals in the environment. While the pharmaceutical industry has argued that the high value of drugs would prevent their release into the environment, this assumption has been proven incorrect. The production of drugs is concentrated in specific locations, often in middle-income countries with less advanced wastewater infrastructure, which can lead to the discharge of active pharmaceutical ingredients (APIs) into waterways.

Agriculture is another major source of pharmaceutical pollution. The use of reclaimed water or livestock waste in agriculture can introduce pharmaceuticals into the land, which can then leach into groundwater or waterways. Large-scale poultry and livestock operations generate significant amounts of animal waste laced with hormones and antibiotics, which can contaminate water sources. Studies have found measurable amounts of medications in a high percentage of water samples drawn from streams across multiple states. Pharmaceutical active compounds (PhACs) have been detected in agricultural soils, and their presence can lead to an imbalance in microorganisms, reducing agricultural efficiency, and potentially impacting human health and the environment.

The presence of pharmaceutical pollutants in water sources has become a growing concern due to their potential impacts on human health and other organisms. Pharmaceuticals can persist in the environment and undergo transformations, leading to complex mixtures of contaminants. While wastewater treatment plants (WWTPs) can remove some pharmaceuticals, they are not currently equipped to filter out all pharmaceutical waste. The removal rates for pharmaceuticals in WWTPs depend on the characteristics of the drugs and the treatment technology, and treated sewage can still contain pharmaceuticals when discharged into the sea.

Pharmaceuticals accumulate in marine sediments, acting as a secondary pollution source

Pharmaceuticals are biologically active compounds that are designed to interact with specific physiological pathways in targeted organisms. They can pose a risk to the health of marine non-target organisms and act as additional stressors on marine ecosystems already impacted by climate change, overfishing, and eutrophication.

Once pharmaceuticals are discharged into aquatic environments, they can undergo biotic and abiotic transformations (degradation) and sorb to suspended particulate matter (SPM) and sediments, and in some cases, accumulate in the tissues of aquatic organisms. Existing data for the environmental fate of pharmaceuticals in freshwater environments may not be applicable to marine environments due to differences in physico-chemical conditions, including salinity, pH, and organic matter.

Sediments act as a reservoir for the accumulation of pharmaceuticals in marine ecosystems and can become a secondary source of pollution. Changes in environmental conditions, such as salinity and pH, can release pharmaceuticals from sediments, and tidal changes and storms can resuspend sediments, exposing marine life to sorbed pharmaceuticals. Since 2000, 22 studies have reported sediment concentrations of pharmaceuticals in estuarine and marine environments, detecting 62 pharmaceuticals and transformation products at concentrations up to 2,615,000 ng g^-1 wet weight. 17α-ethinyloestradiol, a hormone, was detected at the highest concentration of 129.8 ng g^-1.

The sources of pharmaceutical pollution in the ocean include patient use in the community, hospital discharges, wastewater from pharmaceutical manufacturing, and agricultural runoff. Additionally, incorrect disposal of medications by individuals and pharmaceutical companies contributes to the problem, with landfills and sewage treatment plants leaking pharmaceutical waste into the ocean.

The presence of pharmaceuticals in the ocean has raised concerns about their potential impact on marine life and the environment. Aquatic organisms are especially vulnerable to the effects of pharmaceuticals, with increased feminization observed in fish and other aquatic species exposed to birth control pills and hormonal medications. The outbreak of antibiotic-resistant bacteria is another critical issue associated with pharmaceutical pollution in marine waters.

While there is growing interest in researching pharmaceutical residues in the environment, more studies are needed to understand their effects on marine life and the potential risks they pose to human health.

Pharmaceuticals impact aquatic organisms, causing behavioural changes, hormone disruption, and toxicity

Pharmaceuticals are now recognized as contaminants of emerging environmental concern. They have been found in aquatic systems globally, due to a combination of worldwide usage and low removal efficiency in sewage treatment plants (STPs) or a lack of STPs. Even in cases where wastewater is treated, the removal rates for pharmaceuticals in wastewater treatment plants (WWTPs) range from less than 10 to almost 100% and depend on the physico-chemical characteristics of the pharmaceutical and the type of treatment technology.

Sources of human pharmaceuticals in sewage include patient use in the community, discharges from hospitals, and, in some cases, wastewater from pharmaceutical manufacturing. Sewage can be discharged into marine environments through coastal and ocean outfalls for WWTPs, combined sewer overflows, and via rivers receiving WWTP effluents. For example, the Yangtze River in China transports sewage from 400 million people out to sea and releases an estimated 152 tonnes of pharmaceuticals annually.

Sediments are a reservoir for the accumulation of pharmaceuticals in marine ecosystems and can act as a secondary pollution source from which pharmaceuticals can be released by changes in environmental conditions such as salinity and pH. In addition, many people dispose of any unused medication by putting it into their everyday waste and sending it to landfill sites, which often leak their liquid waste directly into the ocean.

The presence of pharmaceuticals in the ocean has been shown to impact aquatic organisms, causing behavioural changes, hormone disruption, and toxicity. Research has shown that many fish and other aquatic species are experiencing increased feminization as a result of their exposure to birth control pills and other hormonal medications disposed of in the oceans. These pharmaceutical effects in smaller species can and will quickly make their way up the food chain, with levels of pharmaceuticals being found in the blood plasma of larger fish and other sea mammals.

The most common chronic toxic effects of pharmaceuticals in non-target aquatic animal species are related to locomotive disorders, endocrine disruption, genotoxicity, reproduction disorders, oxidative stress, body deformations, teratogenic effects, and reductions in overall organism condition (vitality). Other indirect ecological effects of pharmaceutical exposure in aquatic systems may arise through changed population sizes (especially extinctions) and subsequently altered community composition and species richness, as these are known to influence ecosystem functioning.

Bioremediation, such as mycoremediation with fungi, offers a cost-effective solution to treat pharmaceutical pollution

Pharmaceuticals are indeed found in ocean pollution. They enter the ocean through various pathways, including sewage discharge, wastewater from pharmaceutical manufacturing, and agricultural runoff. For example, the Yangtze River in China carries an estimated 152 tonnes of pharmaceuticals into the sea annually.

Bioremediation is a promising solution to address pharmaceutical pollution. It involves using diverse microorganisms to transform toxic pollutants into non-toxic forms. Compared to physical and chemical remediation methods, bioremediation is more cost-effective, environmentally friendly, and sustainable.

Mycoremediation, a type of bioremediation that employs fungi or their derivatives, has been found to be effective in treating pharmaceutical pollution. Various fungi, such as Trametes versicolor, can degrade and eliminate pharmaceutical pollutants, including hydrophobic drugs, polycyclic aromatic hydrocarbons, pesticides, herbicides, and antibiotics.

The advantages of mycoremediation include its cost-effectiveness, eco-friendliness, and ability to address a wide range of pollutants. Additionally, mycoremediation can be applied in situ, where the contaminated site is treated directly, or ex situ, where the pollutants are transported to another location for treatment.

However, it is important to acknowledge that mycoremediation has its limitations, and ongoing research aims to improve its rate and efficiency. Nonetheless, mycoremediation offers a promising and cost-effective solution to treat pharmaceutical pollution, contributing to the protection of human health and the natural environment.

Frequently asked questions